November 5, 2020

TFF Pharmaceuticals and Felix Biotechnology Sign Letter of Intent for a Collaboration, Development and License Agreement

November 2, 2020

TFF Pharmaceuticals, Inc. and Augmenta Bioworks, Inc. Enter Into a Worldwide Joint Development Agreement for COVID-19 Monoclonal Antibody Therapies

October 28, 2020

TFF Pharmaceuticals Announces Third Quarter 2020 Financial Results and Business Update Conference Call on November 5, 2020

October 27, 2020

TFF Pharmaceuticals Announces Positive Preclinical Results with University of Georgia Universal Influenza Vaccines

October 26, 2020

TFF Pharmaceuticals Expands its cGMP Manufacturing Capabilities with Experic

October 20, 2020

TFF Pharmaceuticals Updates Progress of Human Clinical Trial with Tacrolimus Inhalation Powder

September 30, 2020

TFF Pharmaceuticals Announces Results of Its 2020 Annual Meeting of Stockholders

September 24, 2020

TFF Pharmaceuticals Comments on Animal Studies in the Development of High Potency Remdesivir as a Dry Powder for Inhalation by Thin Film Freezing

September 15, 2020

TFF Pharmaceuticals Announces Topline Results of Voriconazole Inhalation Powder Phase 1 Clinical Trial

September 14, 2020

TFF Pharmaceuticals to Participate in Anti-fungal Webinar Presented by Maxim Group LLC on September 17th, 2020